Athersys (NASDAQ:ATHX) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Down 33.5 %

Shares of ATHX opened at $0.01 on Monday. The company has a market cap of $833,206.50, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.